Abstract
Objective To investigate the clinical application value of serum tumor marker carbohydrate antigen (CA50), squamous cell carcinoma antigen(Scc-Ag), gastrin-releasing peptide precursor (ProGRP) combined dynamic detection in the early diagnosis and monitoring of lung cancer. Methods A total of 126 cases of lung cancer (lung cancer group) and 50 cases of lung benign lesions (benign control group) and 50 cases of healthy physical examination (normal control group) were selected as the research objects. Serum tumor marker levels of CA50, Scc-Ag, ProGRP were measured with electrochemiluminescence and ELISA respectively. Results ① Serum CA50, Scc-Ag, ProGRP levels in lung cancer group were significantly higher than those in the benign control group and normal control (P<0.01); ② Serum levels of CA50, Scc-Ag, Pro-GRP before treatment in the high staging lung cancer group and recurrence metastasis group were significantly higher than those in the low staging group, no recurrence transfer group and after treatment of these groups(P<0.01). ③ The serum levels of CA50, Scc-Ag and ProGRP were higher in lung adenocarcinoma, squamous cell carcinoma and small cell carcinoma respectively(P<0.01). ④ The sensitivity of serum CA50, Scc-Ag, ProGRP in the diagnosis of lung cancer was 48.41%, 52.37%, 46.83% respectively, specificity was 96.00%, 98.00%, 94.00% respectively, accuracy was 61.93%, 64.77%, 60.23% respectively.The specificity of combined detection of three tumor markers for diagnosis of lung cancer was 86%, although it decreased, but the sensitivity and accuracy were improved by 95.24% and 92.61% respectively, compared with the individual items and two groups of two combination detection, the difference was significant (P<0.01). Conclusions Serum tumor markers CA50, Scc-Ag and ProGRP can be used as biological markers in the diagnosis of lung cancer, the sensitivity and accuracy of combined detection are obviously improved, which is helpful for early diagnosis, at the same time, combined dynamic detection can help to judge clinical staging, histological type, recurrence metastasis, monitoring prognosis and guiding treatment. Key words: Lung cancer; Tumor markers; Biology; Combined detection; Diagnosis and treatment
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call